News
Aclaris Reports Positive Phase 2a Trial Results
July 30, 2025 • News
Companies mentioned:
Aclaris Therapeutics shares are trading higher after the company announced positive top-line results from its Phase 2a trial of ATI-2138, demonstrating favorable tolerability and efficacy in treating moderate-to-severe atopic dermatitis.